Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Porter

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
Psychopharmacology|January 1, 1981
Drug-associated psychiatric disturbances in medical inpatientsD A Danielson, J B Porter, D H Lawson, et al.
Blood|May 23, 1998
Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell diseaseE Mollapour, J B Porter, R Kaczmarski, et al.
JAMA|December 21, 1984
Drug-induced blood disordersD A Danielson, S W Douglas, P Herzog, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|May 17, 2007
Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stressC Thephinlap, S Ounjaijean, U Khansuwan, et al.
British Journal of Haematology|March 1, 1993
Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor IIJ B Porter, L Young, I J Mackie, et al.
Lancet (London, England)|July 15, 1989
Animal toxicology of iron chelator L1J B Porter, K P Hoyes, R Abeysinghe, et al.
Pharmacotherapy|November 1, 1984
Long-term follow-up study of cimetidineJ B Porter, H Jick, D R Perera, et al.
Skeletal Radiology|September 29, 2005
Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographsS Desigan, M A Hall-Craggs, C-P Ho, et al.
European Journal of Haematology|January 1, 1997
Relationship between the severity of beta-thalassaemia syndromes and the number of alleviating mutationsS Ratip, M Petrou, J M Old, et al.
Acta Haematologica|January 1, 1987
In vivo evaluation of hydroxypyridone iron chelators in a mouse modelM Gyparaki, J B Porter, S Hirani, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Psychopharmacology|January 1, 1981
Drug-associated psychiatric disturbances in medical inpatientsD A Danielson, J B Porter, D H Lawson, et al.
Blood|May 23, 1998
Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell diseaseE Mollapour, J B Porter, R Kaczmarski, et al.
JAMA|December 21, 1984
Drug-induced blood disordersD A Danielson, S W Douglas, P Herzog, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|May 17, 2007
Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stressC Thephinlap, S Ounjaijean, U Khansuwan, et al.
British Journal of Haematology|March 1, 1993
Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor IIJ B Porter, L Young, I J Mackie, et al.
Lancet (London, England)|July 15, 1989
Animal toxicology of iron chelator L1J B Porter, K P Hoyes, R Abeysinghe, et al.
Pharmacotherapy|November 1, 1984
Long-term follow-up study of cimetidineJ B Porter, H Jick, D R Perera, et al.
Skeletal Radiology|September 29, 2005
Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographsS Desigan, M A Hall-Craggs, C-P Ho, et al.
European Journal of Haematology|January 1, 1997
Relationship between the severity of beta-thalassaemia syndromes and the number of alleviating mutationsS Ratip, M Petrou, J M Old, et al.
Acta Haematologica|January 1, 1987
In vivo evaluation of hydroxypyridone iron chelators in a mouse modelM Gyparaki, J B Porter, S Hirani, et al.
Pageof 10